Category: Parkinsonism, Atypical: MSA
Objective: We aim to investigate how structural metabolism of the brain affects survival in patients of multiple system atrophy (MSA).
Background: Multiple system atrophy (MSA) is one of neurodegenerative disease characterized parkinsonism, cerebellar ataxia and autonomic dysfunction. It is known that the prognosis of MSA is a poor, several studies had conducted to determine the predictors of survival. A hypothesis suggested that several structural metabolisms of the brain affect predictors of survival in patients of MSA.
Method: In this retrospective study, we investigated patients with MSA who underwent 18F-FDG PET studies at Asan Medical Center. All patients were diagnosed on the basis of consensus of statement for the diagnosis of MSA. We evaluated Unified Parkinson’s Disease Rating Scale (UPDRS), Unified Multiple System Atrophy Rating Scale (UMSAR), autonomic dysfunction to evaluated symptoms of MSA. Structural metabolism was analyzed from 18fluorodeoxyglucose positron emission tomography (18F FDG PET). We compared the demographics and severity of symptoms the patient of MSA-P and patients of MSA-C. We evaluated correlation of survival and standardized uptake values (SUVs) of brain region, measured by 18F FDG PET, using Cox regression analysis
Results: The study population included 55 patients with MSA. We found no statistical differences in age between the MSA-C group (n=29) and the MSA-P group (n=26) (Median age 58.4±7.1 vs 60.8±8.4, p=0.26). Also, there is no statistical difference in mortality and median survival between the two groups (Median survival time 4.9±2.5 vs 5.5±2.5, p=0.45). We found that hypometabolism of vermis (HR 30.97, 95% CI: 1.96 to 488.4, p=0.015) and midbrain (HR 725.3, 95% CI: 1.03 to 510201, p=0.048) associated with poor prognostic factor of survival in patients with MSA-C. However, there is no statistical associated with survival and metabolic lesion in patients with MSA-P.
Conclusion: We found that glucose hypermetabolism in vermis and midbrain lesion was associated with survival in patients with MAS-C. In this study, we suggest that brain metabolism could be used as a prognostic factor in patients with MSA.
To cite this abstract in AMA style:
S. Lee, S. Jo, J. Lee, S. Chung. Brain metabolism associated with clinical feature in patients with multiple system atrophy [abstract]. Mov Disord. 2023; 38 (suppl 1). https://www.mdsabstracts.org/abstract/brain-metabolism-associated-with-clinical-feature-in-patients-with-multiple-system-atrophy/. Accessed June 14, 2025.« Back to 2023 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/brain-metabolism-associated-with-clinical-feature-in-patients-with-multiple-system-atrophy/